Hudson Executive Capital’s Akoya BioSciences AKYA Stock Holding History

Hudson Executive Capital’s Portfolio AKYA Stock Details AKYA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-1,736,017	Closed	-$14.2M	–	6
2023 Q1	$14.2M	Sell	1,736,017 -478,491	-22%	-$5M	1.69%	4
2022 Q4	$21.2M	Sell	2,214,508 -1,483,050	-40%	-$18.2M	2.26%	4
2022 Q3	$43.4M	Buy	3,697,558 +1,250,000	+51%	+$16.5M	6.22%	3
2022 Q2	$31.5M	Hold	2,447,558	–	–	3.99%	4
2022 Q1	$26.9M	Buy	2,447,558 +45,305	+2%	+$525K	2.15%	5
2021 Q4	$36.8M	Buy	2,402,253 +552,410	+30%	+$7.23M	2.76%	7
2021 Q3	$25.8M	Buy	1,849,843 +779,859	+73%	+$13M	1.82%	8
2021 Q2	$20.7M	Buy	+1,069,984	New	+$22.1M	1.37%	8

Other funds holding AKYA

BWLSA

Blue Water Life Science Advisors Larkspur, California $125M AUM 91.82% 1-Year Est. Return

PCH

Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

BOTOTLSJU

Board of Trustees of The Leland Stanford Junior University Redwood City, California $849M AUM 55.45% 1-Year Est. Return

UIC

Uniplan Investment Counsel Milwaukee, Wisconsin $974M AUM 21.37% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

SVB Wealth Boston, Massachusetts $1.59B AUM 24.57% 1-Year Est. Return

GIM

Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return

PHP

Parkman Healthcare Partners Stamford, Connecticut $970M AUM 79.46% 1-Year Est. Return

Hudson Executive Capital's AKYA Position: Q2 2023 in Review

Hudson Executive Capital sold out of Akoya BioSciences (AKYA) in Q2 2023, closing a stake of 1,736,017 shares — an estimated $14.2M sold.

Hudson Executive Capital first reported a position in AKYA in Q2 2021 and held it in 8 quarters. The position peaked at $43.4M in Q3 2022. 73 funds tracked by Wall St. Rank hold AKYA as of Q2 2023.

Hudson Executive Capital reported no remaining Akoya BioSciences position as of Q2 2023 after selling out during the quarter.
Hudson Executive Capital sold 1,736,017 Akoya BioSciences shares in Q2 2023, an estimated $14.2M.
Hudson Executive Capital first reported a position in Akoya BioSciences in Q2 2021 and held it in 8 quarters.
Hudson Executive Capital's Akoya BioSciences position peaked at $43.4M in Q3 2022.
73 funds tracked by Wall St. Rank held Akoya BioSciences as of Q2 2023.

Based on Hudson Executive Capital's 13F filing for Q2 2023, filed 14 Aug 2023.